More broadly, policies that already acknowledge biomarker “risk enhancers” in primary prevention (e.g., hs‐CRP and Lp(a)) offer a template for integrating diabetes‐relevant stroke biomarkers into shared decision‐making. Here, LPA is linked to diabetes mellitus.